Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)


There are evidences of functional growth hormone (GH) deficiency, expressed by means of low serum levels of insulin-like growth factor 1 (IGF-1), in a subset of fibromyalgia patients. The efficacy of low GH doses versus placebo has been demonstrated in this population. We assessed the efficacy and safety of GH added to standard therapy compared to standard therapy alone in the treatment of severe, prolonged and well-treated fibromialgya patients with low IGF-1 levels.

Full Title of Study: “Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe Fibromialgia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)


  • Drug: sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)
  • Drug: amitriptyline, fluoxetine and tramadol alone (control group)

Clinical Trial Outcome Measures

Primary Measures

  • reduction number of tender points (paired)
    • Time Frame: one year treatment

Secondary Measures

  • improvement in FIQ, EQ-5D , analogic visual scales (1). Safety (2).
    • Time Frame: one year

Participating in This Clinical Trial

Inclusion Criteria

  • Women greater than 18 years old with severe fibromyalgia and abnormally low IGF-1 levels included in a rehabilitation and psychological program and stable under standard intensive treatment for at least 6 months. – All patients fulfilled the 1990 ACR diagnostic criteria (1) and had an IGF-1 level <250 ng/mL (or 1 standard deviation bellow the mean value corresponding to age and body surface according to laboratory reference value). – Other inclusion criteria were duration of fibromyalgia of 1 year or greater, pain in at least 16 (8 bilateral) of the 18 tender points and a score in the FIQ > 75. – The study was conducted in accordance with the Declaration of Helsinki and received the local institutional review board and Spanish Drug Agency (nÂș03-0456) approvals. All patients gave written informed consent prior to their inclusion in the study. Exclusion Criteria:

  • Disabling physical or mental status – Previous or current malignancies, either active or inactive – Intracranial space occupying lesion – Any relevant endocrine disorder including diabetes mellitus – History of another pituitary disorder – Previous treatment with growth hormone – Other systemic or joint inflammatory rheumatic conditions; and – Known to be hypersensitive to somatropin or any of the excipients. – Pregnant women, nursing mothers, or women with childbearing potential not using adequate contraceptive methods were also excluded.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centro Medico Teknon
  • Overall Official(s)
    • Guillem Cuatrecasas, MD, Principal Investigator, CM Teknon Endocrinology Head Department
    • Albert Nadal, MD, Study Chair, CM Teknon Rheumatology Head Department


Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998 Mar;104(3):227-31.

Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-Pesquera F, Casanueva FF, Dieguez C. The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab. 1999 Sep;84(9):3378-81.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.